| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
σ1 receptor (primary target) and σ2 receptor (with lower affinity). (+)-N-Allylnormetazocine hydrochloride is an opioid receptor antagonist (or σ receptor agonist) with Kis of 300 nM for σ1 and 27 microM for σ2 receptors. It is a selective σ1 agonist with much lower affinity for σ2.
|
|---|---|
| ln Vitro |
(+)-N-Allylnormetazocine hydrochloride (1 nM) inhibits opioid receptors μ, δ, and κ by 28.5%, 2.5%, and 31%, respectively[1]. The Ki values of (+)-N-Allylnormetazocine hydrochloride for the σ1 and σ2 opioid receptors are 300 nM and 27 μM, respectively [1].
(+)-N-Allylnormetazocine hydrochloride targets σ1 and σ2 receptors, exhibiting Ki values of 300 nM for σ1 and 27 microM for σ2, indicating approximately 90-fold selectivity for σ1 over σ2. As a selective σ1 receptor agonist, it activates σ1 receptors, which modulate calcium signaling, ER stress responses, and ion channel function. It is behaviorally active in animal models of memory and stress. It has no significant affinity for other opioid receptor subtypes at low concentrations. |
| ln Vivo |
(+)-N-Allylnormetazocine hydrochloride (0.3, 1, 3, 10 and 30 mg/kg; i.p. 10 minutes before each experiment) promotes the dissociative anesthetic effect of phencyclidine (PCP) in a dose-dependent manner[2].
(+)-N-Allylnormetazocine hydrochloride is behaviorally active in animal models of memory and stress. It has been shown to exhibit anti-amnesic effects against scopolamine-induced memory dysfunctions in rats, mediated by σ1 receptor activation. It also modulates cholinergic functions in the hippocampus. It may be used for research on neurological diseases, including Alzheimer‘s disease, depression, and drug addiction. No human clinical efficacy data are available. |
| Enzyme Assay |
Cell-free σ1 receptor binding assays are performed using guinea pig brain membranes or membranes from HEK293 cells expressing human σ1 receptors. Membranes are incubated with 1-5 nM [3H]-pentazocine (a selective σ1 radioligand) and increasing concentrations of (+)-N-Allylnormetazocine (0.01-100,000 nM) in 50 mM Tris-HCl (pH 8.0) containing 100 mM NaCl for 120 min at 25degC. Bound radioactivity is separated by GF/B filtration. Ki values are calculated by nonlinear regression using the Cheng-Prusoff equation. For σ2 binding, rat liver membranes are used with [3H]-DTG in the presence of (+)pentazocine (10 uM) to mask σ1 sites. Ki(σ1) = 300 nM, Ki(σ2) = 27 uM.
|
| Cell Assay |
Cell-based functional assays: HEK293 cells expressing human σ1 receptors are used to assess σ1 agonist activity. Cells are treated with (+)-N-Allylnormetazocine (0.1-1000 uM) and functional readouts include changes in intracellular calcium (using Fluo-4 AM), modulation of reactive oxygen species (ROS) production, or neurite outgrowth in PC12 cells. σ1 activation is known to affect ER-mitochondria calcium transfer, ER stress, and cell survival. The compound can be used to study σ1-mediated neuroprotection, neuritogenesis, and modulation of neurotransmitter systems (e.g., cholinergic, dopaminergic, glutamatergic). For antagonist studies, σ1 antagonists (e.g., haloperidol, NE-100) are co-administered to confirm σ1-mediated effects.
|
| Animal Protocol |
In vivo studies are performed in male Sprague-Dawley rats or Swiss-Webster mice. (+)-SKF 10047 is dissolved in 0.9% saline (or 10% DMSO in saline) and administered intraperitoneally (i.p.) or subcutaneously (s.c.) at doses of 1-20 mg/kg. For memory studies, scopolamine (1-2 mg/kg i.p.) is administered 30 min before training to induce memory deficits. (+)-SKF 10047 is given 15-30 min before the behavioral test. Spatial memory is assessed by the Morris water maze. Passive avoidance memory is tested using a step-through apparatus. For stress studies, (+)-SKF 10047 is administered before forced swim test or elevated plus maze. For cholinergic studies, acetylcholine release in the hippocampus is measured by microdialysis. The anti-amnesic effects of (+)-SKF 10047 are reversed by co-administration of σ1 antagonists (haloperidol, NE-100). No published PK protocols for this specific salt form.
|
| ADME/Pharmacokinetics |
No specific PK data are reported for (+)-N-Allylnormetazocine hydrochloride. The molecular weight of the hydrochloride salt is 297.82 (C17H24ClNO). The free base MW is 261.38. CAS# 133005-41-1. Purity ≥98%. Storage: room temperature, protect from light. Solubility: water (10-25 mg/mL), DMSO, ethanol. The compound is centrally active and crosses the BBB after systemic administration, as evidenced by its behavioral effects in memory and stress models following i.p. injection. Half-life (t1/2) in rats is not reported but is likely 1-3 hours based on typical σ1 agonist pharmacology. Clearance is moderate. Oral bioavailability is not reported.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for (+)-N-Allylnormetazocine hydrochloride. In published studies at doses up to 20 mg/kg i.p. in rats, no signs of acute toxicity (seizures, severe motor impairment, or death) were observed. However, as a σ1 agonist, it may produce behavioral effects including modulation of locomotor activity and stress responses at higher doses. Standard toxicological assessments (hERG, Ames, repeat-dose toxicity) have not been performed. No FDA approval. Not for human use. Not for clinical trials.
|
| References |
|
| Additional Infomation |
Other information: (+)-N-Allylnormetazocine hydrochloride ((+)-SKF 10047) is a research compound, not FDA-approved. CAS# 133005-41-1. It is the prototypical and most widely used selective σ1 receptor agonist in pharmacological research. It is valuable for studying σ1 receptor function in memory, learning, stress responses, neuroprotection, pain, and drug addiction. It also has opioid receptor antagonist activity at higher concentrations. It is a controlled substance in some jurisdictions. For research use only.
|
| Molecular Formula |
C17H24CLNO
|
|---|---|
| Molecular Weight |
293.83
|
| Exact Mass |
293.155
|
| CAS # |
133005-41-1
|
| PubChem CID |
13286169
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.842
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@@H]1[C@@H]2CC3=C([C@]1(CCN2CC=C)C)C=C(C=C3)O.Cl
|
| InChi Key |
ZTGMHFIGNYXMJV-XSCGHNKWSA-N
|
| InChi Code |
InChI=1S/C17H23NO.ClH/c1-4-8-18-9-7-17(3)12(2)16(18)10-13-5-6-14(19)11-15(13)17;/h4-6,11-12,16,19H,1,7-10H2,2-3H3;1H/t12-,16+,17+;/m1./s1
|
| Chemical Name |
(1S,9S,13S)-1,13-dimethyl-10-prop-2-enyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4033 mL | 17.0166 mL | 34.0333 mL | |
| 5 mM | 0.6807 mL | 3.4033 mL | 6.8067 mL | |
| 10 mM | 0.3403 mL | 1.7017 mL | 3.4033 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
